Literature DB >> 2508048

Branhamella catarrhalis bronchopulmonary isolates in PICU patients.

G F Kasian1, S D Shafran, E M Shyleyko.   

Abstract

Branhamella catarrhalis is commonly considered a respiratory commensal but has recently been implicated as a pathogen, particularly in adults. Over a 28 month period, B. catarrhalis was isolated from bronchopulmonary secretions of 14 PICU patients with acute respiratory infections. Twelve patients had pneumonia and two had tracheitis. The mean age was 3.5 years. Seven patients had chronic cardiopulmonary disease including two who were immunosuppressed. Three had an acute underlying condition and four had no complicating medical problem. Polymorphs and Gram-negative diplococci on Gram stain were found in respiratory secretions of all patients. Twelve of 14 isolates produced beta-lactamase, and six patients had a second potentially pathogenic bronchopulmonary isolate. All patients were treated for B. catarrhalis infection and none died. When isolated in pure culture from bronchopulmonary secretions in symptomatic patients, B. catarrhalis should be considered a pathogen. When isolated in mixed culture, its pathogenic role is uncertain. We conclude that B. catarrhalis can be a bronchopulmonary pathogen in critically ill children with otherwise normal cardiopulmonary function as well as in those with chronic cardiopulmonary dysfunction. When administering antibiotics the high frequency of beta-lactamase-producing strains must be taken into consideration.

Entities:  

Mesh:

Year:  1989        PMID: 2508048     DOI: 10.1002/ppul.1950070303

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  2 in total

1.  Molecular epidemiological characterization of respiratory isolates of Moraxella catarrhalis in a pediatric intensive care unit.

Authors:  A G Matlow; D E Low; G Paret; S Jarrett; D Bohn; G Barker; J Boulanger; E L Ford-Jones
Journal:  Can J Infect Dis       Date:  1992-07

Review 2.  Infraglottic and bronchial infections.

Authors:  A Uba
Journal:  Prim Care       Date:  1996-12       Impact factor: 2.907

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.